HighTide Unit Launches Diabetes-Kidney Drug Study with Chinese Academy; Shares Rise 2%
MT Newswires Live
Aug 13
HighTide Therapeutics (HKG:2511) said its wholly owned subsidiary, Shenzhen HighTide Biopharmaceutical, has launched a research collaboration with the Institute of Medicinal Biotechnology under the Chinese Academy of Medical Sciences, according to a Tuesday Hong Kong bourse filing.
The project will study the company's lead drug candidate, HTD1801, for type 2 diabetes with chronic kidney disease.
Shares of HighTide gained 2% in Wednesday late-afternoon trade.
The collaboration will assess HTD1801's multi-indication potential, targeting improvements in blood glucose, kidney and liver function, lipids, cardiovascular health, body weight, and inflammation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.